Literature DB >> 11351041

Monoclonal light chain--mesangial cell interactions: early signaling events and subsequent pathologic effects.

W J Russell1, J Cardelli, E Harris, R J Baier, G A Herrera.   

Abstract

Glomerulopathic monoclonal light chains (G-LC) interact with mesangial cells (MC), resulting in alterations of mesangial homeostasis. Early signaling events control mitogenic activities and cytokine production, which in turn participate in the subsequent pathologic events. Mesangial homeostasis is affected in two very different ways, depending on whether the G-LC is from a patient with light chain deposition disease (LCDD) or light chain-related amyloidosis (AL-Am). In contrast, tubulopathic (T)-LC chains from patients with myeloma cast nephropathy do not significantly interact with MC and result in no alterations in mesangial homeostasis. Therefore, understanding early events in the monoclonal LC-MC interactions is fundamental. MC in culture were exposed to LC obtained and purified from the urine of patients with plasma cell dyscrasias and biopsy-proven renal disease, including LCDD, AL-Am, and myeloma cast nephropathy. Incubation of MC with G-LC, but not T-LC, resulted in cytoskeletal and cell shape changes, activation of platelet-derived growth factor-beta (PDGF-beta) and its corresponding receptor, cytoplasmic to nuclear migration of c-fos and NF-kappa beta signals, and production of monocyte chemoattractant protein-1 (MCP-1), as well as increased expression of Ki-67, a proliferation marker. Although NF-kappa beta activation was directly related to MCP-1 production, c-fos activation regulated proliferative signals and cytoskeletal changes in MC. Amyloidogenic LC were avidly internalized by the MC, whereas LCDD-LC effector targets were located at the MC surface. These cellular events are likely initiated as a result of interactions of the G-LC with yet-uncharacterized MC surface receptors. Dissecting the events taking place when G-LC interact with MC may define potential important targets for selective therapeutic manipulation to ameliorate or prevent the glomerular injury that ensues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11351041     DOI: 10.1038/labinvest.3780278

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  4 in total

1.  Glomerulopathic Light Chain-Mesangial Cell Interactions: Sortilin-Related Receptor (SORL1) and Signaling.

Authors:  Guillermo A Herrera; Luis Del Pozo-Yauner; Jiamin Teng; Chun Zeng; Xinggui Shen; Takahito Moriyama; Veronica Ramirez Alcantara; Bing Liu; Elba A Turbat-Herrera
Journal:  Kidney Int Rep       Date:  2021-03-13

2.  Heavy-chain deposition disease: a morphological, immunofluorescence and ultrastructural assessment.

Authors:  Swapnil Rane; Seema Rana; Chetan Mudrabettu; Vivekananda Jha; Kusum Joshi
Journal:  Clin Kidney J       Date:  2012-10

Review 3.  The pathogenesis of renal injury and treatment in light chain deposition disease.

Authors:  Qi Wang; Fang Jiang; Gaosi Xu
Journal:  J Transl Med       Date:  2019-11-25       Impact factor: 5.531

4.  Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts.

Authors:  Grace Fortes Monis; Christopher Schultz; Ruiyi Ren; Jeremy Eberhard; Catherine Costello; Lawreen Connors; Martha Skinner; Vickery Trinkaus-Randall
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.